Viewing Study NCT02502266

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:33 PM
Ignite Modification Date: 2026-02-28 @ 8:50 PM
Study NCT ID: NCT02502266
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-01
First Post: 2015-07-17
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
Sponsor: National Cancer Institute (NCI)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Fallopian Tube Clear Cell Adenocarcinoma View
None Fallopian Tube Endometrioid Adenocarcinoma View
None Fallopian Tube Serous Adenocarcinoma View
None Fallopian Tube Transitional Cell Carcinoma View
None Fallopian Tube Undifferentiated Carcinoma View
None Ovarian Clear Cell Adenocarcinoma View
None Ovarian Endometrioid Adenocarcinoma View
None Ovarian Seromucinous Carcinoma View
None Ovarian Serous Adenocarcinoma View
None Ovarian Transitional Cell Carcinoma View
None Ovarian Undifferentiated Carcinoma View
None Primary Peritoneal Serous Adenocarcinoma View
None Recurrent Fallopian Tube Carcinoma View
None Recurrent Ovarian Carcinoma View
None Recurrent Primary Peritoneal Carcinoma View
Keywords: